3rd NovAliX Conference

Biophysics in Drug Discovery 2016

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

 Strasbourg, France    June 7-10, 2016

Committee


Conference Chairman

Dr J.-P. RENAUD

NovAliX & Ribostruct, Illkirch, France

Scientific Committee

Dr J. BRYSON

Bristol-Myers-Squibb, Princeton, United States

Dr C.-W. CHUNG

GlaxoSmithKline, Stevenage, United Kingdom

Prof. H. DANIELSON

Uppsala University, Uppsala, Sweden

Dr U. EGNER

Bayer, Berlin, Germany

Dr M. HENNIG

leadXpro, Villigen, Switzerland

Dr G. HOLDGATE

AstraZeneca, Macclesfield, United Kingdom

Prof. R. HUBBARD

University of York & Vernalis, Cambridge, United Kingdom

Prof. G. KLEBE

Philipps-University Marburg, Marburg, Germany

Dr H. NAR

Boehringer Ingelheim, Biberach, Germany

Dr J. OTTL

Novartis Institute of Biomedical Research, Basel, Switzerland

Dr J.-P. RENAUD

NovAliX & Ribostruct, Illkirch, France